Ninety-one percent of pharmaceutical and life sciences executives surveyed by HRI said patients will increasingly manage their health at home over the next 10 years through pharma patient engagement services such as drug adherence programs and health management apps. Of those that haven’t used remote data collection for trials, 25 percent said they will consider trial protocols with remote data collection in the next two years. Seventy-nine percent of executives from the largest companies said they would.
Biopharma R&D won’t be able to shift to fully remote trials overnight, but the transition is happening; taking steps now to build organizational support for new trial designs, protocol feasibility, patient identification and overall stakeholder management and communication is critical. These companies need to consider novel trial designs with platforms that use artificial intelligence and data sets generated in the real world, using digital devices.